mTORC1 Selective Nano-Inhibitor by Disrupting the Lysosomal Arginine-SLC38A9- mTORC1-CDKs Axis for Precision Bladder...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Clinical translation of nanomedicines is hindered by lack of precise targeting and defined mechanisms.
• Mammalian target of rapamycin complex 1 (mTORC1) is crucial for cell proliferation and metabolism, with abnormal activation implicated in diseases like cancer.
• Existing small-molecule mTORC1 inhibitors have limitations, driving the need for novel therapeutic strategies.

Purpose of the Study:

• To develop novel mTORC1-specific nano-inhibitors targeting the lysosomal arginine-SLC38A9-mTORC1 pathway.
• To investigate the efficacy and specificity of these nanomedicines compared to existing treatments.
• To explore the potential of these nano-inhibitors for precise cancer therapy, particularly non-muscle invasive bladder cancer (NMIBC).

Main Methods:

• Utilized a [2Fe-2S]CO6 paradigm to engineer nanomedicines (e.g., ZnPc-SFeCO) capable of degrading lysosomal arginine.
• Assessed nanomedicine efficacy by measuring mTORC1 inhibition, specificity against rapamycin, and the impact of SLC38A9 knockout.
• Evaluated differential responses in normal and bladder cancer cells based on SLC38A9 expression.
• Conducted in vivo studies combining nanomedicines with photodynamic therapy for NMIBC treatment, comparing outcomes to MMC.

Main Results:

• Developed ZnPc-SFeCO nanomedicine that inhibits mTORC1 at ultra-low concentrations (1.07 ng mL-1) with high specificity.
• Demonstrated that SLC38A9 knockout completely abolished nanomedicine efficacy, confirming the targeted pathway.
• Observed differential responses in normal versus bladder cancer cells, correlating with SLC38A9 expression levels.
• In vivo, ZnPc-SFeCO combined with photodynamic therapy showed superior efficacy over MMC in preventing tumor recurrence and extending survival.

Conclusions:

• Established a strategy for developing mTORC1-specific nano-inhibitors with well-defined targets and mechanisms.
• Highlighted the potential of these nano-inhibitors for precise cancer therapy, especially NMIBC, by exploiting differential SLC38A9 expression.
• Provided new insights into precision nanomedicine development for cancer treatment.